TGA designates two new orphan drugs
This article was originally published in Scrip
Australia's Therapeutics Goods Administration (TGA) has designated two new orphan drugs. These are GlaxoSmithKline's Revolade (eltrombopag olamine) tablets, for the treatment of idiopathic thrombocytopenic purpura and Novartis's Afinitor (everolimus) 5mg and 10mg tablets, for the treatment of advanced renal cell carcinoma . Both were designated status on July 17th.